Skip to content
TrustList
CTI Life Sciences Fund logo
Venture capital firm

CTI Life Sciences Fund

Boutique venture capital firm investing in life sciences companies in Canada, the United States and Europe

CTI Life Sciences Fund cover

About CTI Life Sciences Fund

A company builder with an exit-focused thesis

A knowledge-driven boutique venture capital firm focused on life sciences, CTI Life Sciences Fund says it combines collective intelligence to deliver results on investments in the field. It presents itself as a company builder that catalyzes emerging science and assets into biotech companies that can be invested in, scaled and marketed. Its mission covers Canada, the United States and Europe, and the firm aims to deliver innovations and returns across biotechnology and healthcare. It describes its investing as therapeutic and modality agnostic.

An exit-focused investment thesis

The firm's thesis rests on the view that strategic buyers will pay a premium for biotech companies with strong assets or platforms. It therefore pursues two aims at once: long-term value creation and a faster route to an exit. Its team steers each investment toward a meaningful exit by drawing on industry expertise and a wide network, and takes biotech investments from inception through to inflection point.

Team background in pharma research and finance

The partners bring a mix of skills. A founding general partner has more than twenty years at the firm and over thirty years in finance and investment banking. Another has more than a decade of running investments and building new portfolio companies. A third brings more than 25 years of pharmaceutical research and development leadership, from project start through clinical development and technology transfer, and a founding team member has played a pivotal role in every fund since 2006. The firm says its skills span diligence, deal execution and portfolio oversight.

Portfolio spanning therapies and platforms

Portfolio examples on the site include a company with a first-in-class autophagy-driven treatment for metastatic pancreatic cancer, a clinical-stage biotherapeutics company developing mTORC1-specific inhibitors, and a cardiology business built around a precision asset from a Montreal heart research institute. The site also refers to a program aimed at urologists and to a company working on tumor-specific antigen identification. The firm says its portfolio companies have brought treatments to thousands of patients and fueled growth in the local innovation ecosystem.

Recent financings and launches

News from the site covers a financing to speed development of immuno-oncology and inflammation therapies, a company rebranding to focus on GPCR-modulating therapies, and the launch of a precision siRNA company by the fund. It also reports an FDA clearance for a candidate for long QT syndrome and the start of a Phase 2b study for a treatment for a rare inherited disorder. These items show the firm's activity from early creation of companies through to clinical trials.

TrustList summary

CTI Life Sciences Fund is a small venture capital firm that invests in life sciences businesses. It works across Canada, the United States and Europe, and its stated aim is to back emerging science and help companies grow into scalable businesses. Its investments span biotechnology and healthcare.

Services

  • Venture investment: funding for scalable life sciences companies at an early stage of development.
  • Scientific and financial judgement: decisions drawn from a team with drug development, banking and biotech investing backgrounds.
  • Company-building support: help for founders in shaping business objectives and reaching their potential value.

Who it works with

Life sciences, biotechnology and healthcare companies in Canada, the United States and Europe that have strong scientific ideas and room to scale.

Key facts

  • Structure: several managing partners, including a founding partner of the fund franchise
  • Team background: investment banking, portfolio management, mergers and acquisitions, asset licensing and pharmaceutical research
  • Regions: Canada, the United States and Europe
  • Sector: life sciences

Summary written by TrustList from the business's own published information, Nov 2026.

Categories & features

Ask TrustList to introduce you to CTI Life Sciences Fund

TrustList reads every request before passing it on, and sends it only where the funder's stage and focus look like a fit. We do not charge for introductions, and we cannot promise a reply.

Protected by reCAPTCHA - Google Privacy Policy and Terms apply.

Reviews

Write the first review of CTI Life Sciences Fund

Used it? Your experience helps other buyers decide.

Write a review

Questions & answers

No questions yet. Be the first to ask about CTI Life Sciences Fund.

CTI Life Sciences Fund alternatives

Similar listings buyers compare against this one.

Member-based investor group funding early-stage companies through monthly review and a chapter roadshow

Venture capital firm backing pre-seed deep technology startups in health and planetary sustainability

Venture capital firm partnering with founders from first idea through to public listing

Silicon Valley venture capital firm investing from seed to growth stage across technology sectors

Global venture capital firm and accelerator backing early-stage technology founders, formerly called 500 Startups

Venture capital firm backing founders it calls outliers, with a portfolio spanning software and climate technology

Investment company focused on esports, blockchain, payments and other new technologies

Early-stage investor in European software and sustainability companies